Accelerated approval
May 24, 2017
FDA grants accelerated approval to pembrolizumab
The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co.) for adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
